Table 3.
Correlation of genetic mutation with histopathological outcomes [N = 44]
| Histopathology |
BRAF |
NRAS |
HRAS |
None |
|---|---|---|---|---|
| V600E | detected | |||
| PTC (13) | 7 (53.8%) | 1 (7.6%) | 0 (0%) | 5 (38.4%) |
| Nodal PTC (6) metastases | 4 (66.7%) | 0 | 0 | 2 (33.3%) |
| FVPTC (5) | 1 (20%) | 1 (20%) | 0 | 3 (60%) |
| Follicular (8) Carcinoma | 0 | 5 (62.5%) | 2 (25%) | 1 (12.5%) |
| PD carcinoma (1) | 0 | 0 | 0 | 1 (100%) |
| Hurthle cell (1) Carcinoma | 0 | 0 | 0 | 1 (100%) |
| Follicular (7) Adenoma | 0 | 1 (14.3%) | 1 (14.3%) | 5 (71.4%) |
| Hurthle cell (1) Adenoma | 0 | 0 | 0 | 1 (100%) |
| Multinodular (2) Goiter | 0 | 0 | 0 | 2 (100%) |
| Total (44) | 12 | 8 | 3 | 21 |
PTC- Papillary thyroid carcinoma; FVPTC- Follicular variant of PTC; PD-poorly differentiated